WallStreetZenWallStreetZen

NASDAQ: BBLG
Bone Biologics Corp Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their BBLG stock forecasts and price targets.

Forecast return on equity

Is BBLG forecast to generate an efficient return?

Company
-34.27%
Industry
13.12%
Market
136.35%
BBLG's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is BBLG forecast to generate an efficient return on assets?

Company
-31.71%
Industry
10.04%
BBLG is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BBLG earnings per share forecast

What is BBLG's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$1.20
Avg 2 year Forecast
-$0.60

BBLG revenue forecast

What is BBLG's revenue in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0

BBLG vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
BBLG$0.38N/AN/A
TNON$2.05N/AN/A
IVF$1.91N/AN/A
NXL$1.60N/AN/A
VJET$0.59N/AN/A
View Top Medical Device Stocks

Bone Biologics Stock Forecast FAQ

What is BBLG's earnings growth forecast for 2026-2027?

(NASDAQ: BBLG) Bone Biologics's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 54.14%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 1,326.1%.

Bone Biologics's earnings in 2026 is -$2,841,984.On average, 3 Wall Street analysts forecast BBLG's earnings for 2026 to be -$4,079,069, with the lowest BBLG earnings forecast at -$3,919,106, and the highest BBLG earnings forecast at -$4,199,042.

In 2027, BBLG is forecast to generate -$2,039,535 in earnings, with the lowest earnings forecast at -$1,959,553 and the highest earnings forecast at -$2,099,521.

If you're new to stock investing, here's how to buy Bone Biologics stock.

What is BBLG's revenue growth forecast for 2026-2027?

(NASDAQ: BBLG) Bone Biologics's forecast annual revenue growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 5.3%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 19.71%.

Bone Biologics's revenue in 2026 is $0.On average, 3 Wall Street analysts forecast BBLG's revenue for 2026 to be $0, with the lowest BBLG revenue forecast at $0, and the highest BBLG revenue forecast at $0.

In 2027, BBLG is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is BBLG's forecast return on assets (ROA) for 2026-2027?

(NASDAQ: BBLG) forecast ROA is -36.01%, which is lower than the forecast US Medical Devices industry average of 10.13%.

What is BBLG's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: BBLG) Bone Biologics's current Earnings Per Share (EPS) is -$1.17. On average, analysts forecast that BBLG's EPS will be -$1.20 for 2026, with the lowest EPS forecast at -$1.16, and the highest EPS forecast at -$1.24. In 2027, BBLG's EPS is forecast to hit -$0.60 (min: -$0.58, max: -$0.62).

What is BBLG's forecast return on equity (ROE) for 2026-2027?

(NASDAQ: BBLG) forecast ROE is -38.91%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.